Cardiff Oncology entered into formal separation agreements with former CEO Dr. Mark Erlander and former CFO James Levine on March 27, 2026. Dr. Erlander will receive a $635,000 base salary payout over 12 months, a $122,238 bonus for 2025, and 50% of his 2026 target bonus. Mr. Levine will receive a $490,000 base salary payout over 12 months, a $61,740 bonus for 2025, and 50% of his 2026 target bonus. Both executives receive 12 months of continued healthcare benefits and have agreed to general releases and confidentiality terms. Dr. Erlander will provide consulting services to the company, and his stock options will continue to vest until June 2026.